Major Pharmaceutical and Biotechnology Companies of the World ...
Major Pharmaceutical and Biotechnology Companies of the World ...
Major Pharmaceutical and Biotechnology Companies of the World ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
00936 CHEMI DAROU INDUSTRIAL COMPANY IRAN<br />
Status: Private Company<br />
00936<br />
CHEMI DAROU INDUSTRIAL COMPANY<br />
Address: PO Box 16575-361, Next to Saipa Co, 3km Mark,<br />
Abali Road, Tehran<br />
International tel: +98 (21) 7733 0291<br />
International fax: +98 (21) 7733 6458<br />
Company email: info@chemidarou.com<br />
Website: www.chemidarou.com<br />
Board <strong>of</strong> Directors: Ali Jabbari (Managing Director)<br />
PRINCIPAL ACTIVITIES: Manufacture <strong>of</strong> pharmaceuticals,<br />
polyvinyl acetate resins <strong>and</strong> textile auxiliaries<br />
Ticker Symbol: KIMI1<br />
Stock Exchange: TSE<br />
ISIN: IRO1KIMI0001<br />
Status: Public Company<br />
Date <strong>of</strong> Establishment: 1965<br />
No <strong>of</strong> Employees: 350<br />
Financial Information:<br />
20.3.10 20.3.11<br />
IR’000 IR’000<br />
Sales turnover 498,833,000 450,475,000<br />
Pr<strong>of</strong>it before tax 143,277,000 134,427,000<br />
Pr<strong>of</strong>it after tax 112,370,000 115,478,000<br />
Earnings per share IR936 IR481<br />
Share capital 120,000,000 240,000,000<br />
Shareholders’ equity 333,545,000 370,223,000<br />
00937<br />
CINNAGEN COMPANY<br />
Address: 5th Floor, 56 Azimi St, Phase 1, Shahrak Ekbatan,<br />
Tehran<br />
International tel: +98 (211) 4466 6203<br />
International fax: +98 (211) 4466 4991<br />
Company email: info@cinnagen.com;sales@cinnagen.com<br />
Website: www.cinnagen.com<br />
Management: Dr Haleh Hamedifar (President)<br />
PRINCIPAL ACTIVITIES: Molecular biology <strong>and</strong> biotechnology<br />
company, producing diagnostic/research reagents including<br />
blood grouping reagents, PCR kits <strong>and</strong> reagents, HIV kits,<br />
T3 T4 kits, LHRH, molecular biology reagents <strong>and</strong> CA, PH<br />
<strong>and</strong> CL diagnostic kits<br />
Status: Private Company<br />
Date <strong>of</strong> Establishment: 1994<br />
00938<br />
COSAR PHARMACEUTICAL COMPANY<br />
Address: 32, 6th Alley, Ahmad Qasir Street, Abbas Abad<br />
Street, 15147-17811 Tehran<br />
International tel: +98 (211) 8873 7401<br />
International fax: +98 (211) 8873 2664<br />
Telex: 223243 CSPH-IR<br />
Website: www.cosarpharm.com<br />
Board <strong>of</strong> Directors: Faramarz Shariat (Managing Director)<br />
PRINCIPAL ACTIVITIES: Manufacture <strong>and</strong> idstribution <strong>of</strong> pharmaceuticals,<br />
particularly antibiotic finished products such<br />
as Ampicillin, Amoxicillin <strong>and</strong> Cloxacillin<br />
<strong>Major</strong> Products: Antibiotics oral forms<br />
Trade Names: Irapen, Iramox, Cloxiran, Co-Amoxiclav, Garlet<br />
Principal Banks: Bank Tejarat<br />
Auditors: Rahbord Argham Co<br />
Ticker Symbol: DKSR1<br />
Stock Exchange: TSE<br />
ISIN: IRO1DKSR0001<br />
Status: Public Company<br />
Date <strong>of</strong> Establishment: 1975<br />
No <strong>of</strong> Employees: 230<br />
Financial Information:<br />
20.3.10 20.3.11<br />
IR’000 IR’000<br />
Sales turnover 424,078,000 295,540,000<br />
Pr<strong>of</strong>it before tax 64,944,000 45,264,000<br />
Pr<strong>of</strong>it after tax 52,200,000 45,264,000<br />
Earnings per share IR387 IR251<br />
Share capital 135,000,000 180,000,000<br />
Shareholders’ equity 230,911,000 220,875,000<br />
120<br />
00939<br />
DAMLORAN PHARMACEUTICAL COMPANY<br />
Address: 7 Parvin Street, West Dr Fatemi Avenue, 14186<br />
Tehran<br />
International tel: +98 (21) 6694 5732; +98 (21) 939 690;<br />
+98 (21) 885 6907<br />
International fax: +98 (662) 6694 5736 (Factory);<br />
+98 (21) 651325<br />
Telex: 212710 DVPL IR<br />
Company email: damloran@damloran.com<br />
Website: www.damloran.com/<br />
Board <strong>of</strong> Directors: Ahmad Karbasi (Managing Director)<br />
PRINCIPAL ACTIVITIES: Manufacture <strong>and</strong> distribution <strong>of</strong><br />
veterinary pharmaceuticals<br />
Trade Names: Damloran<br />
Ticker Symbol: DAML1<br />
Stock Exchange: TSE<br />
ISIN: IRO1DAML0001<br />
Status: Public Company<br />
Date <strong>of</strong> Establishment: 1983<br />
No <strong>of</strong> Employees: 220<br />
Financial Information:<br />
20.3.10 20.3.11<br />
IR’000 IR’000<br />
Sales turnover 300,752,000 367,850,000<br />
Pr<strong>of</strong>it before tax 61,988,000 70,110,000<br />
Pr<strong>of</strong>it after tax 48,396,000 54,654,000<br />
Earnings per share IR1,367 IR1,544<br />
Share capital 35,400,000 35,400,000<br />
Shareholders’ equity 113,486,000 126,710,000<br />
00940<br />
DAROU PAKHSH (HOLDING) COMPANY<br />
Address: Darou Pakhsh Street, 18km Mark, Tehran-Karaj<br />
Highway, Tehran<br />
International tel: +98 (21) 4498 6815<br />
International fax: +98 (21) 4498 7314<br />
Company email: info@dppharma.com<br />
Website: www.dppharma.ir<br />
Board <strong>of</strong> Directors: Ahmad Sheybani (Managing Director)<br />
PRINCIPAL ACTIVITIES: Investment holding company with<br />
subsidiaries involved in <strong>the</strong> manufacture <strong>and</strong> marketing <strong>of</strong><br />
pharmaceuticals<br />
Subsidiary <strong>Companies</strong>: (100% owned unless stated): Darou<br />
Pakhsh <strong>Pharmaceutical</strong>s Company; Darou Pakhsh <strong>Pharmaceutical</strong>s<br />
Manufacturing Company<br />
Ticker Symbol: DARO1<br />
Stock Exchange: TSE<br />
ISIN: IRO1DARO0001<br />
Status: Public Company<br />
No <strong>of</strong> Employees: 3,420<br />
Financial Information:<br />
20.3.10 20.3.11<br />
IR’000 IR’000<br />
Income 580,950,000 701,416,000<br />
Pr<strong>of</strong>it before tax 574,325,000 729,997,000<br />
Pr<strong>of</strong>it after tax 573,869,000 727,834,000<br />
Earnings per share IR956 IR1,213<br />
Share capital 600,000,000 600,000,000<br />
Shareholders’ equity 1,349,373,000 1,583,474,000<br />
00941<br />
DAROU PAKHSH PHARMACEUTICALS<br />
COMPANY<br />
Address: Darou Pakhsh Street, 18km Mark, Tehran-Karaj<br />
Highway, Tehran<br />
International tel: +98 (21) 4498 6815<br />
International fax: +98 (21) 4498 7314<br />
Company email: info@dppharma.com<br />
Website: www.dppharma.ir<br />
PRINCIPAL ACTIVITIES: Wholesale <strong>of</strong> pharmaceuticals<br />
Parent Company: Darou Pakhsh (Holding) Company (00940)<br />
Ticker Symbol: DDPK1<br />
Stock Exchange: TSE<br />
ISIN: IRO1DDPK0001<br />
Status: Public Company<br />
Principal Shareholders: Darou Pakhsh (Holding) Company<br />
No <strong>of</strong> Employees: 260<br />
Financial Information:<br />
20.3.10 20.3.11<br />
IR’000 IR’000<br />
Sales turnover 266,136,000 280,825,000<br />
Pr<strong>of</strong>it before tax 25,525,000 36,521,000<br />
Pr<strong>of</strong>it after tax 19,956,000 28,779,000<br />
Earnings per share IR570 IR822<br />
Share capital 35,000,000 35,000,000<br />
Shareholders’ equity 57,981,000 68,860,000<br />
00942<br />
DAROU PAKHSH PHARMACEUTICALS<br />
MANUFACTURING COMPANY<br />
Address: Darou Pakhsh Street, 18km Mark, Tehran-Karaj<br />
Highway, Tehran<br />
International tel: +98 (21) 4498 6815<br />
International fax: +98 (21) 4498 7314<br />
Company email: info@dppharma.com<br />
Website: www.dppharma.ir<br />
PRINCIPAL ACTIVITIES: Manufacture <strong>of</strong> pharmaceuticals<br />
Parent Company: Darou Pakhsh (Holding) Company (00940)<br />
Ticker Symbol: DPAK1<br />
Stock Exchange: TSE<br />
ISIN: IRO1DPAK0001<br />
Status: Public Company<br />
Principal Shareholders: Darou Pakhsh (Holding) Company<br />
Financial Information:<br />
20.3.10 20.3.11<br />
IR’000 IR’000<br />
Sales turnover 1,003,667,000 1,101,409,000<br />
Pr<strong>of</strong>it before tax 264,658,000 274,454,000<br />
Pr<strong>of</strong>it after tax 200,316,000 213,605,000<br />
Earnings per share IR2,003 IR1,068<br />
Share capital 100,000,000 200,000,000<br />
Shareholders’ equity 389,685,000 433,290,000<br />
00943<br />
DOCTOR ABIDI LABORATORIES COMPANY<br />
Address: 8km Mark, Karaj Special Road Boulevard, Tehran<br />
International tel: +98 (21) 4450 4785<br />
International fax: +98 (21) 4450 4787<br />
Company email: info@abidipharma.com<br />
Website: www.doctor-abidi.com<br />
Board <strong>of</strong> Directors: M Hasan Baradaran Ghasemi (Managing<br />
Director)<br />
PRINCIPAL ACTIVITIES: Manufacture <strong>of</strong> pharmaceuticals<br />
Ticker Symbol: ABDI1<br />
Stock Exchange: TSE<br />
ISIN: IRO1ABDI0001<br />
Status: Public Company<br />
No <strong>of</strong> Employees: 250<br />
Financial Information:<br />
20.3.10 20.3.11<br />
IR’000 IR’000<br />
Sales turnover 376,023,000 443,887,000<br />
Pr<strong>of</strong>it before tax 121,529,000 102,595,000<br />
Pr<strong>of</strong>it after tax 98,894,000 80,810,000<br />
Earnings per share IR1,766 IR1,443<br />
Share capital 56,000,000 56,000,000<br />
Shareholders’ equity 190,291,000 213,901,000<br />
00944<br />
EXIR PHARMACEUTICAL COMPANY<br />
Address: PO Box 14335-379, 22 Rahmati Alley, Vali-e Asr,<br />
Tehran<br />
International tel: +98 (21) 8891 8461<br />
International fax: +98 (21) 8889 9358<br />
Company email: info@exir.co.ir<br />
Website: exir.co.ir<br />
Board <strong>of</strong> Directors: Gholam Hossain Farz<strong>and</strong>i (Managing<br />
Director)<br />
PRINCIPAL ACTIVITIES: Manufacture <strong>of</strong> pharmaceuticals<br />
Ticker Symbol: EXIR1<br />
Stock Exchange: TSE<br />
ISIN: IRO1EXIR0001<br />
Status: Public Company<br />
No <strong>of</strong> Employees: 590
03590 ACINO HOLDING AG SWITZERLAND<br />
Company email: info.ch@abbott.com<br />
Website: www.abbott.ch<br />
Company Registration Number: CH-280.3.910.125-8<br />
Management Board: Jacopo Andreose (Chairman), Robert<br />
Lüthi (Member), Peter Reinert (Member)<br />
PRINCIPAL ACTIVITIES: Development <strong>and</strong> manufacture <strong>of</strong><br />
pharmaceuticals <strong>and</strong> nutritional products, <strong>and</strong> products<br />
for diabetes care, laboratory diagnostics, vascular disease<br />
treatment <strong>and</strong> molecular diagnostics. ISO 9001 <strong>and</strong> ISO<br />
14001 certified<br />
Company History: The company was previously known as<br />
Knoll AG <strong>and</strong> subsequently as Abbott Liestal AG<br />
Branch Offices: Altish<strong>of</strong>en; Beringen<br />
Parent Company: Abbott Laboratories, USA<br />
Principal Banks: UBS<br />
Auditors: Deloitte AG<br />
Status: Private Company<br />
Principal Shareholders: Abbott Laboratories, USA (100%)<br />
Date <strong>of</strong> Establishment: 1893<br />
No <strong>of</strong> Employees: 140 (Company) 300 (Switzerl<strong>and</strong>)<br />
03590<br />
ACINO HOLDING AG<br />
Address: Erlenstrasse 1, 4058 Basel<br />
International tel: +41 (61) 338 60 00; +41 (61) 775 80 10<br />
International fax: +41 (61) 338 60 06<br />
Company email: info@acino-pharma.com<br />
Website: www.acino-pharma.com<br />
Company Registration Number: CH-270.3.002.367-6<br />
Board <strong>of</strong> Directors: Luzi Andreas von Bidder (Chairman), Dr<br />
René Muttenzer (Vice Chairman), Dr Anders Härfstr<strong>and</strong> (Director),<br />
Hans Peter Hasler (Director), Jürg Michel (Director)<br />
Executive Board: Peter Burema (Chief Executive Officer), Dr<br />
Jean-Daniel Bonny (Head <strong>of</strong> Research <strong>and</strong> Development),<br />
Dr Annette Eschler (Head <strong>of</strong> Business Development), Jörg<br />
Gebhardt (Head <strong>of</strong> IT <strong>and</strong> Human Resources), Dr Harald<br />
Haubitz (Head <strong>of</strong> Production), Ruud van Anraat (Chief Commercial<br />
Officer), Marcel von Ah (Chief Financial Officer)<br />
PRINCIPAL ACTIVITIES: Research, development, manufacture<br />
<strong>and</strong> distribution <strong>of</strong> speciality pharmaceuticals <strong>and</strong><br />
value-added generics<br />
Company History: September 2008: Schweizerhall Holding<br />
AG changed its company name to Acino Holding AG. Simultaneously<br />
<strong>the</strong> business units Cimex <strong>and</strong> Novosis joined<br />
forces under <strong>the</strong> common company name Acino<br />
Subsidiary <strong>Companies</strong>: (100% owned unless stated): Acino<br />
AG (Germany); Acino Pharma AG; Acino Pharma GmbH<br />
(Germany); Acino Pharma Inc (USA); Acino Supply AG<br />
Principal Banks: UBS; CS<br />
Auditors: PricewaterhouseCoopers AG<br />
Ticker Symbol: ACIN<br />
Stock Exchange: Swiss<br />
ISIN: CH0002159413<br />
Status: Public Company<br />
Principal Shareholders: Chase Nominees Ltd, UK (18.2%);<br />
Marianne <strong>and</strong> Dr Hans-Peter Schär (8.2%)<br />
No <strong>of</strong> Employees: 443 (Group)<br />
Financial Information: Consolidated figures<br />
31.12.09 31.12.10<br />
EUR’000 EUR’000<br />
Revenue 158,181 127,533<br />
Pr<strong>of</strong>it (loss) before tax 41,837 (6,027)<br />
Pr<strong>of</strong>it after tax 33,501 4,518<br />
Earnings per share 10.53EUR 1.42EUR<br />
Share capital 823 823<br />
Shareholders’ equity 256,017 252,585<br />
03591<br />
ACTAVIS<br />
Actavis Group<br />
Address: Turmstrasse 24, 6300 Zug<br />
International tel: +41 (41) 462 73 00<br />
Website: www.actavis.com<br />
Company Registration Number: CH-170.9.001.398-2<br />
Executive Board: Dr Claudio Albrecht (Chief Executive Officer),<br />
Gunnar A Beinteinsson (Executive Vice President.<br />
Human Resources <strong>and</strong> OD), Doug Boo<strong>the</strong> (Executive Vice<br />
President, Americas Sales), Gudbjorg Edda Eggertsdottir<br />
(President Icel<strong>and</strong>, Strategic Projects), Guðrun S Eyjolfsdottir<br />
(Executive Vice President, Quality <strong>and</strong> Compliance),<br />
Mark Keatley (Executive Vice President, Finance), Wolter<br />
Kuizinga (Executive Vice President, Business Development),<br />
Roy Papa<strong>the</strong>odorou (Executive Vice President <strong>and</strong> General<br />
Counsel), Preter Prock (Deputy Chief Executive Officer),<br />
464<br />
Valur Ragnarsson (Executive Vice President, Third-Party<br />
Sales), Lars Ramneborn (Executive Vice President, Europe<br />
Sales), Jeff Rope (Executive Vice President <strong>of</strong> Operations),<br />
Frank Staud (Executive Vice President - Corporate Communications,<br />
Br<strong>and</strong>ing <strong>and</strong> Sponsoring), Stefan J Sveinsson<br />
(Executive Vice President, Research <strong>and</strong> Development),<br />
Hordur Thorhallsson (Executive Vice President, MEA <strong>and</strong><br />
Asia Pacific Sales)<br />
PRINCIPAL ACTIVITIES: Production <strong>of</strong> generic pharmaceuticals<br />
Company History: The company was privatised in 2007. In<br />
May 2011 it moved its headquarters to Switzerl<strong>and</strong><br />
Branch Offices: Bulgaria; Icel<strong>and</strong>; India; Indonesia; Italy;<br />
Malta; PRC; Romania; Russia; Serbia; UK; USA<br />
Subsidiary <strong>Companies</strong>: (100% owned unless stated): Actavis<br />
Deutschl<strong>and</strong> GmbH & Co KG (Germany); Actavis EAD<br />
(Bulgaria); Actavis Operations EOOD (Bulgaria); Actavis<br />
Pharma Development Centre Private Limited (India); Actavis<br />
Romania SRL (Romania); Actavis UK Limited (UK)<br />
Status: Private Company<br />
Date <strong>of</strong> Establishment: 1956<br />
No <strong>of</strong> Employees: 10,000 (<strong>World</strong>wide)<br />
03592<br />
ACTELION PHARMACEUTICALS LTD<br />
Address: Gewerbestrasse 16, 4123 Allschwil<br />
International tel: +41 (61) 565 65 65;<br />
+41 (61) 487 34 58 (Media/Investor Contacts)<br />
International fax: +41 (61) 565 65 00<br />
Company email: info@actelion.com;jobs.ch@actelion.com<br />
Website: www.actelion.com<br />
Company Registration Number: CH-280.3.003.028-8<br />
Board <strong>of</strong> Directors: Jean-Pierre Garnier (Chairman), Jean-<br />
Paul Clozel (Chief Executive Officer), Juhani Anttila (Director),<br />
Robert Bertolini (Director), Marian Borovsky (Senior<br />
Vice President, Group General Counsel <strong>and</strong> Corporate<br />
Secretary), Robert E Cawthorn (Director), Carl Feldbaum<br />
(Director), Werner Henrich (Director), Michael Jacobi (Director),<br />
Armin Kessler (Director), Jean Malo (Director)<br />
Executive Committee: Christian Albrich (Senior Vice President<br />
<strong>and</strong> Head <strong>of</strong> Global Human Resources), Guy Braunstein (Executive<br />
Vice President <strong>and</strong> Head <strong>of</strong> Clinical Development),<br />
Rol<strong>and</strong> Haefeli (Senior Vice President <strong>and</strong> Head <strong>of</strong> Investor<br />
Relations <strong>and</strong> Public Affairs)<br />
Management Board: Simon Buckingham (Senior Global<br />
Advisor), Louis de Lassence (Vice President <strong>and</strong> Head <strong>of</strong><br />
Corporate Services), Nicholas Franco (Executive Vice President<br />
<strong>and</strong> Chief Business Development Officer), Isaac Kobrin<br />
(Senior Vice President <strong>and</strong> Chief Medical Officer), Andrew<br />
J Oakley (Executive Vice President <strong>and</strong> Chief Financial Officer),<br />
Otto Schwarz (Executive Vice President <strong>and</strong> Chief<br />
Operating Officer)<br />
PRINCIPAL ACTIVITIES: Bio-pharmaceutical company focusing<br />
on <strong>the</strong> research, development <strong>and</strong> marketing <strong>of</strong><br />
syn<strong>the</strong>tic small molecule drugs to treat <strong>and</strong> prevent diseases<br />
related to <strong>the</strong> endo<strong>the</strong>lium. Actelion Ltd is <strong>the</strong> holding<br />
<strong>and</strong> finance company <strong>of</strong> <strong>the</strong> Group. Actelion <strong>Pharmaceutical</strong>s<br />
Ltd, based in Allschwil, a 100% subsidiary <strong>of</strong> Actelion<br />
Ltd, is in charge <strong>of</strong> <strong>the</strong> discovery, development, registration,<br />
production, quality assurance, safety, marketing coordination,<br />
group management <strong>and</strong> coordination. Actelion<br />
<strong>Pharmaceutical</strong>s Ltd fur<strong>the</strong>r holds <strong>the</strong> intellectual property<br />
rights <strong>of</strong> <strong>the</strong> Group<br />
Trade Names: Tracleer (R), Ventavis (R), Zavesca (R)<br />
Subsidiary <strong>Companies</strong>: (100% owned unless stated): Actelion<br />
Clinical Research Inc (USA); Actelion Cyprus Ltd<br />
(Cyprus); Actelion Finance SCA (Luxembourg); Actelion<br />
Ilac Ticaret LS (Turkey); Actelion Luxembourg SARL (Luxembourg);<br />
Actelion One SA (Luxembourg); Actelion Participation<br />
GmbH; Actelion Partners SNC (Luxembourg);<br />
Actelion Pharma Polska Sp zoo (Pol<strong>and</strong>); Actelion Pharma<br />
Schweiz AG; Actelion <strong>Pharmaceutical</strong>s Australia Pty Ltd<br />
(Australia); Actelion <strong>Pharmaceutical</strong>s Austria GmbH (Austria);<br />
Actelion <strong>Pharmaceutical</strong>s Belgium NV (Belgium);<br />
Actelion <strong>Pharmaceutical</strong>s Canada Inc (Canada); Actelion<br />
<strong>Pharmaceutical</strong>s CZ sro (Czech Republic); Actelion <strong>Pharmaceutical</strong>s<br />
Deutschl<strong>and</strong> GmbH (Germany); Actelion <strong>Pharmaceutical</strong>s<br />
do Brasil Ltda (Brazil); Actelion <strong>Pharmaceutical</strong>s<br />
España SL (Spain); Actelion <strong>Pharmaceutical</strong>s France SASU<br />
(France); Actelion <strong>Pharmaceutical</strong>s Hellas SA (Greece);<br />
Actelion <strong>Pharmaceutical</strong>s Hungaria LLC (Hungary); Actelion<br />
<strong>Pharmaceutical</strong>s India Private Ltd (India); Actelion <strong>Pharmaceutical</strong>s<br />
Israel Ltd (Israel); Actelion <strong>Pharmaceutical</strong>s<br />
Italia Srl (Italy); Actelion <strong>Pharmaceutical</strong>s Japan Ltd (Japan);<br />
Actelion <strong>Pharmaceutical</strong>s Korea Ltd (South Korea); Actelion<br />
<strong>Pharmaceutical</strong>s Ltd (CH); Actelion <strong>Pharmaceutical</strong>s Mexico<br />
SA de CV (Mexico); Actelion <strong>Pharmaceutical</strong>s Nederl<strong>and</strong> BV<br />
(Ne<strong>the</strong>rl<strong>and</strong>s); Actelion <strong>Pharmaceutical</strong>s Portugal (Portugal);<br />
Actelion <strong>Pharmaceutical</strong>s RUS LLC (Russia); Actelion <strong>Pharmaceutical</strong>s<br />
(Shanghai) Company Ltd (People’s Republic <strong>of</strong><br />
China); Actelion <strong>Pharmaceutical</strong>s Singapore Pte Ltd (Singapore);<br />
Actelion <strong>Pharmaceutical</strong>s SK sro (Slovakia); Actelion<br />
<strong>Pharmaceutical</strong>s Sverige AB (Sweden); Actelion <strong>Pharmaceutical</strong>s<br />
Taiwan Ltd (Taiwan); Actelion <strong>Pharmaceutical</strong>s UK<br />
Ltd (UK); Actelion <strong>Pharmaceutical</strong>s US Inc (USA); Actelion<br />
Re SA (Luxembourg); Actelion Registration Ltd (UK); Actelion<br />
US Holding Company (USA); Areus Inc (USA); CoTherix<br />
Inc (USA)<br />
Auditors: Ernst & Young AG<br />
Ticker Symbol: ATLN<br />
Stock Exchange: Swiss<br />
ISIN: CH0010532478<br />
Status: Public Company<br />
Date <strong>of</strong> Establishment: 1997<br />
No <strong>of</strong> Employees: 1,600 (Group worldwide)<br />
Financial Information: Consolidated figures<br />
31.12.10 31.12.11<br />
SF’000 SF’000<br />
Revenue 1,928,969 1,796,063<br />
Pr<strong>of</strong>it (loss) before tax 440,861 (69,301)<br />
Pr<strong>of</strong>it (loss) after tax 390,557 (146,319)<br />
Earnings (loss) per share 3.28SF (1.23SF)<br />
Share capital 64,912 65,232<br />
Shareholders’ equity 1,795,204 1,510,454<br />
03593<br />
ADD TECHNOLOGIES AG<br />
Former name: ADD Advanced Drug Delivery Technologies<br />
AG<br />
Address: Kägenstrasse 17, 4153 Reinach<br />
International tel: +41 (61) 715 97 00<br />
International fax: +41 (61) 715 97 01<br />
Company email: info@addtechnologies.com<br />
Website: www.addtechnologies.com<br />
Company Registration Number: CH-280.3.000.972-7<br />
Board <strong>of</strong> Directors: Reinhard Nowak (Chairman), Dr Hans<br />
Leuenberger (Director), Hans Rudolf Lötscher (Director), Jay<br />
Nowak (Director)<br />
PRINCIPAL ACTIVITIES: Development, manufacture <strong>and</strong><br />
sale <strong>of</strong> enhanced pharmaceutical <strong>and</strong> biopharmaceutical<br />
multiparticulate products<br />
Company History: The company was previously known as<br />
ADD Advanced Drug Delivery Technologies AG<br />
Auditors: Testor Treuh<strong>and</strong><br />
Status: Private Company<br />
Principal Shareholders: Glatt <strong>Pharmaceutical</strong> Services<br />
03594<br />
ADDEX PHARMACEUTICALS LTD<br />
Addex Pharma SA<br />
Address: 12 chemin des Aulx, 1228 Plans-les-Ouates<br />
International tel: +41 (22) 884 15 55<br />
International fax: +41 (22) 884 15 56<br />
Company email: addex-hr@addexpharma.com<br />
Website: www.addexpharma.com<br />
Company Registration Number: CH-660.0.659.007-3<br />
Board <strong>of</strong> Directors: André J Mueller (Chairman), Vincent<br />
Lawton (Vice Chairman), Andrew Galazka (Director), Dr<br />
Raymond Hill (Director), Dr Hoyoung Huh (Director), Oleg<br />
Nodelman (Director), Antoine Papiernik (Director)<br />
Management: Dr Bharatt Chowrira (President <strong>and</strong> Chief<br />
Executive Officer), Tim Dyer (Chief Financial Officer), Dr<br />
Laurent Galibert (Head <strong>of</strong> Metabolism <strong>and</strong> Inflammation<br />
Projects), Charlotte Keywood (Chief Medical Officer), Robert<br />
Lütjens (Head <strong>of</strong> Biology), Chris Maggos (Head <strong>of</strong> Investor<br />
Relations <strong>and</strong> Communication), Dr Sonia Poli (Head <strong>of</strong><br />
Non-Clinical Development <strong>and</strong> CNS Projects), Tatiana Pont-<br />
Carteret (Head <strong>of</strong> Human Resources), Jean-Philippe Rocher<br />
(Head <strong>of</strong> Chemistry)<br />
PRINCIPAL ACTIVITIES: Development, production <strong>and</strong> marketing<br />
<strong>of</strong> drugs <strong>and</strong> medicines for <strong>the</strong> treatment <strong>of</strong> addictions,<br />
physical ailments <strong>and</strong> neuropsychiatric conditions. The<br />
company develops allosteric modulators, small molecule<br />
<strong>the</strong>rapeutic agents that may <strong>of</strong>fer more sophisticated ways<br />
to normalise biological signalling perturbed by disease<br />
compared to classical “orthosteric” agonist or antagonist<br />
drugs. Addex focuses on <strong>the</strong> discovery <strong>and</strong> development<br />
<strong>of</strong> allosteric modulators which target G-Protein Coupled
04139 INTERVET COLOMBIA LTDA COLOMBIA<br />
Financial Information:<br />
31.12.09 31.12.10<br />
COP’000 COP’000<br />
Sales turnover 283,304,936 332,030,284<br />
Pr<strong>of</strong>it before tax 19,895,040 39,974,950<br />
Pr<strong>of</strong>it after tax 11,551,519 27,291,319<br />
Share capital 38,409,684 38,409,684<br />
Shareholders’ equity 160,815,558 175,383,976<br />
04139<br />
INTERVET COLOMBIA LTDA<br />
Address: Avenida Carrera 68 N0 17-64, Costado Occidental,<br />
Bogotá DC<br />
International tel: +57 (1) 417 5466<br />
International fax: +57 (1) 676 1080<br />
Website: www.intervet.com.co<br />
Company Registration Number: 830015923<br />
Management: Angelo Bolis Delair (Representante Legal),<br />
Steven Koehler (Gerente), Ricardo Rodriguez Chala (Contador),<br />
Michiel Stijn (Gerente)<br />
PRINCIPAL ACTIVITIES: Wholesale trade in animal healthcare<br />
products<br />
Parent Company: Merck & Co Inc., USA<br />
Status: Limited Liability Company<br />
Principal Shareholders: Merck & Co Inc., USA<br />
Financial Information:<br />
31.12.09 31.12.10<br />
COP’000 COP’000<br />
Sales turnover 26,164,750 41,509,987<br />
Pr<strong>of</strong>it before tax 1,626,129 5,345,163<br />
Pr<strong>of</strong>it after tax 943,607 3,505,693<br />
Share capital 777,550 777,550<br />
Shareholders’ equity 3,740,314 7,064,340<br />
04140<br />
JOHNSON & JOHNSON DE COLOMBIA S.A.<br />
J&J DE COLOMBIA SA<br />
Address: Apartado Postal 6530, Calle 15 No.31-146,<br />
Yumbo, Valle del Cauca<br />
International tel: +57 (2) 651 3333<br />
International fax: +57 (2) 651 3462<br />
Website: www.jnjcolombia.com.co<br />
Company Registration Number: 890101815<br />
Board <strong>of</strong> Directors: Martha Lucia Echeverry Piñeres (Director),<br />
Walter Grundy (Director), Adolfo Ignacio Ibarra Garcia<br />
(Director), Rosana Padilla Guevara (Representante Legal),<br />
Álvaro Palacio Restrepo (Gerente)<br />
Management: Luis Casallas Jimenez (Contador)<br />
PRINCIPAL ACTIVITIES: Manufacture <strong>of</strong> toiletries <strong>and</strong> pharmaceuticals<br />
Parent Company: Johnson & Johnson, USA<br />
Status: Non Quoted Public Company<br />
Principal Shareholders: Johnson & Johnson, USA<br />
Date <strong>of</strong> Establishment: 5 December 1962<br />
Financial Information:<br />
31.12.09 31.12.10<br />
COP’000 COP’000<br />
Sales turnover 618,617,523 661,504,288<br />
Pr<strong>of</strong>it before tax 67,776,661 68,557,686<br />
Pr<strong>of</strong>it after tax 42,723,961 46,464,929<br />
Share capital 1,852,846 1,852,846<br />
Shareholders’ equity 287,559,498 282,683,276<br />
04141<br />
LABORATORIOS BAXTER S.A.<br />
Address: Apartado Postal 2446, Calle 36 No.2C-22, Cali<br />
International tel: +57 (2) 444 7275; +57 (2) 444 7000<br />
International fax: +57 (2) 444 7412<br />
Website: www.latinoamerica.baxter.com/colombia<br />
Company Registration Number: 890300292<br />
Management: Mario Ciardelli Medina (Representante Legal),<br />
César Augusto González Ospina (Gerente), Carlos Alberto<br />
Roldan Aragon (Gerente), Hector Fauro Vargas Gutierrez<br />
(Contador)<br />
PRINCIPAL ACTIVITIES: Manufacture <strong>of</strong> pharmaceuticals<br />
Parent Company: Baxter International Inc, USA<br />
Status: Non Quoted Public Company<br />
Principal Shareholders: Baxter International Inc, USA<br />
536<br />
Financial Information:<br />
31.12.09 31.12.10<br />
COP’000 COP’000<br />
Sales turnover 525,103,917 547,374,636<br />
Pr<strong>of</strong>it before tax 122,665,101 159,258,131<br />
Pr<strong>of</strong>it after tax 83,187,057 107,577,164<br />
Share capital 1,000,926 1,000,926<br />
Shareholders’ equity 465,921,888 493,688,083<br />
04142<br />
MERCK S.A.<br />
Address: Calle 10 No. 65 28, Bogotá DC<br />
International tel: +57 (1) 425 4770<br />
International fax: +57 (1) 420 7819<br />
Company email: mcsa@merck.com.co<br />
Website: www.merck.com.co<br />
Company Registration Number: 860000580<br />
Board <strong>of</strong> Directors: Hernán Alfonso Briceño Rodríguez (Representante<br />
Legal), Carlos Arturo García Montoya (Director),<br />
Esteban Serrano Luciano (Director)<br />
Management: Luz Mery López Lagos (Gerente), Gladys Stella<br />
Lorenzana Huertas (Contador)<br />
PRINCIPAL ACTIVITIES: Manufacture <strong>of</strong> chemicals for use in<br />
<strong>the</strong> pharmaceutical <strong>and</strong> <strong>of</strong> pharmaceutical preparations<br />
Parent Company: Merck KGaA (02705)<br />
Status: Non Quoted Public Company<br />
Principal Shareholders: Merck KGaA, Germany<br />
Date <strong>of</strong> Establishment: 1957<br />
No <strong>of</strong> Employees: 523<br />
Financial Information:<br />
31.12.09 31.12.10<br />
COP’000 COP’000<br />
Sales turnover 320,061,690 278,006,162<br />
Pr<strong>of</strong>it before tax 73,916,856 37,215,672<br />
Pr<strong>of</strong>it after tax 50,079,535 24,879,572<br />
Share capital 14,356,030 14,356,030<br />
Shareholders’ equity 124,538,491 105,894,170<br />
04143<br />
NOVARTIS DE COLOMBIA S.A.<br />
NOVARTIS<br />
Address: Apartado Postal 123234, Calle 11 No.65-51,<br />
Bogotá DC<br />
International tel: +57 (1) 654 4444<br />
International fax: +57 (1) 446 4815<br />
Website: www.novartis.com<br />
Company Registration Number: 860002538<br />
Board <strong>of</strong> Directors: Maria Cristina Alvarez Rodriguez (Representante<br />
Legal), Jean Claude Dubos (Director), Carlos<br />
Dicken Garcia Iragorri (Director)<br />
Management: Carlos Leonardo Garcia Hewitt (Gerente),<br />
Evelyn Peña (Contador), Guillermo José Quintero Perdomo<br />
(Gerente)<br />
PRINCIPAL ACTIVITIES: Wholesale trade in pharmaceuticals<br />
aiming to prevent <strong>and</strong> cure diseases, to ease suffering <strong>and</strong><br />
to enhance <strong>the</strong> quality <strong>of</strong> life<br />
Parent Company: Novartis AG (03653)<br />
Status: Non Quoted Public Company<br />
Principal Shareholders: Novartis AG, Switzerl<strong>and</strong> (100%)<br />
Financial Information:<br />
31.12.09 31.12.10<br />
COP’000 COP’000<br />
Sales turnover 321,017,516 361,448,213<br />
Pr<strong>of</strong>it before tax 19,983,915 38,131,536<br />
Pr<strong>of</strong>it after tax 13,739,070 23,252,553<br />
Share capital 7,934,807 7,934,807<br />
Shareholders’ equity 113,709,095 100,584,514<br />
04144<br />
PFIZER S.A.<br />
PFIZER<br />
Address: Avenida El Dorado No.68B-85, Bogotá DC<br />
International tel: +57 (1) 417 8507<br />
International fax: +57 (1) 427 0070<br />
Website: www.pfizer.com.co<br />
Company Registration Number: 860039561<br />
Board <strong>of</strong> Directors: Luis Alberto Acuña González (Director),<br />
Luis Fern<strong>and</strong>o Molano (Director), Francisco A Rodríguez<br />
Rodríguez (Director)<br />
Management: Juan Carlos Avila Bustos (Contador), Claudia<br />
Johanna Bohorquez Leon (Gerente), Andres Jordan Herrera<br />
(Representante Legal)<br />
PRINCIPAL ACTIVITIES: Wholesale trade in pharmaceuticals<br />
for human <strong>and</strong> veterinary use<br />
Parent Company: Pfizer Inc, USA<br />
Status: Non Quoted Public Company<br />
Principal Shareholders: Pfizer Inc, USA<br />
Financial Information:<br />
31.12.09 31.12.10<br />
COP’000 COP’000<br />
Sales turnover 280,354,399 472,014,510<br />
Pr<strong>of</strong>it before tax 32,416,267 21,092,880<br />
Pr<strong>of</strong>it after tax 18,947,634 13,203,872<br />
Share capital 30,332,357 30,332,357<br />
Shareholders’ equity 91,080,461 81,304,138<br />
04145<br />
PROCTER & GAMBLE COLOMBIA LTDA<br />
P & G Colombia Ltda<br />
Address: Apartado Postal 94611, Carrera 7 No.114-33, Piso<br />
12, Bogotá DC<br />
International tel: +57 (1) 520 8000<br />
International fax: +57 (1) 640 0013<br />
Website: www.pg.com<br />
Company Registration Number: 800000946<br />
Management: Carlos Alfredo Giraldo Aly (Representante Legal),<br />
Rafael Molina (Contador), Juan David Valencia Ocampo<br />
(Gerente), Víctor Karlo Velazquez Patron (Gerente)<br />
PRINCIPAL ACTIVITIES: Wholesale trade in personal care<br />
products, household cleaning items, laundry detergents,<br />
prescription drugs <strong>and</strong> disposable nappies<br />
Trade Names: Ariel, Pantele, Pert Plus, Camay, Crest<br />
Parent Company: Procter & Gamble Company, USA<br />
Status: Limited Liability Company<br />
Principal Shareholders: Procter & Gamble Company, USA<br />
Financial Information:<br />
31.12.09 31.12.10<br />
COP’000 COP’000<br />
Sales turnover 691,831,680 753,006,926<br />
Pr<strong>of</strong>it before tax 20,194,656 65,237,458<br />
Pr<strong>of</strong>it after tax 8,916,973 42,511,884<br />
Share capital 32,212,968 32,212,968<br />
Shareholders’ equity 194,600,815 200,152,052<br />
04146<br />
PRODUCTOS ROCHE S.A.<br />
Address: Carrera 44 No.17-21, Bogotá DC<br />
International tel: +57 (1) 417 8860<br />
International fax: +57 (1) 337 9270<br />
Website: www.roche.com.co<br />
Company Registration Number: 860003216<br />
Board <strong>of</strong> Directors: Hector Feliu (Director), Rolf Erik Honger<br />
(Representante Legal), Jorg Michael Rupp (Director)<br />
Management: Rodrigo Alonso Gómez Burbano (Gerente),<br />
Edith Marisol López Borbón (Contador)<br />
PRINCIPAL ACTIVITIES: Wholesale trade in pharmaceuticals<br />
Parent Company: Roche Holding AG (03668)<br />
Status: Non Quoted Public Company<br />
Principal Shareholders: Roche Holding AG, Switzerl<strong>and</strong><br />
(100%)<br />
Financial Information:<br />
31.12.09 31.12.10<br />
COP’000 COP’000<br />
Sales turnover 553,829,987 556,832,268<br />
Pr<strong>of</strong>it before tax 26,838,624 11,262,446<br />
Pr<strong>of</strong>it after tax 18,173,009 9,224,135<br />
Share capital 26,923,689 26,923,689<br />
Shareholders’ equity 202,200,282 218,813,820<br />
04147<br />
SANOFI-AVENTIS PHARMA S.A.<br />
SANOFI<br />
Address: Apartado Postal 6161, Transversal 23 N. 97-73,<br />
Piso 9, Bogotá DC<br />
International tel: +57 (1) 621 8400<br />
International fax: +57 (1) 621 4400<br />
Website: www.san<strong>of</strong>i-aventis.com<br />
Company Registration Number: 830010337<br />
Board <strong>of</strong> Directors: Mauricio Botero Caicedo (Representante<br />
Legal), Stephen Edward Cobhan Scott (Director), Jesus<br />
Hern<strong>and</strong>o Cubides Ballesteros (Director)<br />
Management: Giovanni Castillo Moreno (Contador), Hern<strong>and</strong>o<br />
Suárez Ramírez (Gerente)
Change language